Boston Scientific (NYSE:BSX) has agreed to acquire medical device company SoniVie for around $360M upfront payment. As a strategic investor in SoniVie, Boston Scientific currently holds an equity ...

Boston Scientific (NYSE: BSX) is buying into the business of acquisitions. The Marlborough medical device firm has announced its second acquisition thus far in 2025. Boston Scientific Corp. has ...

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire ...

Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ultrasound-based therapy for stubbornly high blood pressure. The acquisition sets up ...

Boston Scientific led a $175 million investment in heart disease device developer 4C Medical Technologies. The investment, which 4C Medical disclosed Wednesday, will support an ongoing pivotal ...

Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire SoniVie, a privately held medical device company that has developed the Tivus Intravascular Ultrasound System.

After the sale of its atrial fibrillation-focused startup to Boston Scientific earlier this year, Ajax Health and KKR are teaming up with the medtech once more to launch a new venture aimed at ...

(RTTNews) - Boston Scientific Corp. (BSX), Monday announced its decision to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System.

Medical device giant Boston Scientific has announced that it has signed a definitive agreement to acquire Israeli medical device company SoniVie for an immediate payment of $360 million as well as ...

As a strategic investor in SoniVie, Boston Scientific currently holds an equity stake of around 10%. The transaction consists ...